




OPEN ACCESS

# High incidence of asymptomatic genital tract infections in pregnancy in adolescent girls and young women: need for repeat aetiological screening

Vani Govender <sup>1,2</sup>, Dhayendre Moodley,<sup>1,2</sup> Megeshinee Naidoo,<sup>1</sup> Cathy Connoly,<sup>3</sup> Sinaye Ngcapu,<sup>1,4</sup> Quarraisha Abdool Karim<sup>1</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/sextrans-2022-055658>).

<sup>1</sup>Centre for the AIDS Program of Research in South Africa, CAPRISA, Durban, KwaZulu-Natal, South Africa

<sup>2</sup>Obstetrics and Gynaecology, University of KwaZulu-Natal College of Health Sciences, Durban, KwaZulu-Natal, South Africa

<sup>3</sup>Department of Biostatistics, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa

<sup>4</sup>Department of Medical Microbiology, University of KwaZulu-Natal College of Health Sciences, Durban, KwaZulu-Natal, South Africa

## Correspondence to

Vani Govender, Women's Health and HIV Research Unit, CAPRISA, Durban 4013, South Africa; [chettyv1@gmail.com](mailto:chettyv1@gmail.com)

Received 6 October 2022

Accepted 10 April 2023

Published Online First

19 May 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Govender V, Moodley D, Naidoo M, et al. *Sex Transm Infect* 2023;**99**:482–488.

## ABSTRACT

**Introduction** Sexually transmitted infection (STI) prevalence and incidence estimates for pregnant adolescents are under-reported. We estimated prevalence and incidence of STIs in pregnant adolescents (15–19 years) in comparison with pregnant women 20–24 and >25 years.

**Methods** Pregnant women registering at primary care clinics in Umlazi, a periurban subdistrict in KwaZulu-Natal, South Africa, were enrolled in an HIV incidence cohort study during February 2017–March 2018. Women were examined for abnormal vaginal discharge, received empirical treatment, tested for HIV-1 and had vaginal swabs taken at their first and a subsequent visit in the third trimester. Vaginal swabs were stored for STI testing at completion of study and tested for *Trichomonas vaginalis*, *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Mycoplasma genitalium* using PCR.

**Results** A total of 752 HIV-negative pregnant women were enrolled at a median gestational age of 17 weeks: 180 (23.9%), 291 (38.7%) and 281 (37.4%) in the 15–19, 20–24 and >25 years age groups. Pregnant adolescents had an STI prevalence of 26.7% at baseline, not significantly lower than the 20–24 (34.7%, OR 1.4; 95% CI 1.0 to 2.1, p=0.09) and >25 years (33.8%, OR 1.4; 95% CI 0.9 to 2.1, p=0.12) age groups. *T. vaginalis* (11.1%), *C. trachomatis* (7.8%) and *N. gonorrhoeae* (4.4%) were most prevalent in adolescents, a trend similar to the other age groups. Overall, 43.4% were symptomatic and treated at baseline. Overall, 40.7% (118 of 290) of women who tested negative for an STI at baseline tested positive at the repeat visit (incidence 19.5/100 person years). STI incidence in pregnant adolescents was 23.9/100 person years and comparable with older age groups (20.5/100 person years and 16.2/100 person years). At the repeat visit, 19.0% of all women with an STI were symptomatic and treated. Performance of syndromic management was poor at baseline (negative predictive value (NPV) 68.6%, positive predictive value (PPV) 34.0%) and at repeat visit (NPV 58.4%, PPV 34.3%).

**Conclusions** Prevalence of asymptomatic curable STIs in pregnant adolescents is high and comparable with women >20 years old. Adolescents remain at substantial risk of asymptomatic incident STIs during pregnancy.

## INTRODUCTION

Adolescent girls (15–19 years) bear a disproportionate burden of HIV infections compared with boys. In sub-Saharan Africa, six in seven new HIV

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ While the high prevalence and the limitations of syndromic diagnosis of sexually transmitted infections (STIs) and bacterial vaginosis in pregnancies are well documented, pregnant adolescents have been understudied. Furthermore, it is well-known that condom use during pregnancy is inconsistent or non-existent and pregnant women, particularly pregnant adolescents, are at continued risk of incident or recurrent STIs throughout pregnancy. Such evidence for the need for repeat aetiological screening for other genital tract infections in pregnancy is lacking in low/middle-income countries.

## WHAT THIS STUDY ADDS

⇒ Prevalence of largely asymptomatic genital tract infections in adolescents at antenatal registration is high. Adolescents and young women are at high risk of asymptomatic incident STIs in the third trimester of pregnancy and may be missed if aetiological screening for STIs is not repeated.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Current Centers for Disease Control and Prevention recommendations include rescreening for STIs in the third trimester of pregnancy, a strategy amiss in the WHO and South African Guidelines. We provide novel evidence for repeat aetiological testing for genital tract infections in the third trimester.

infections among adolescents (15–19 years) are among girls.<sup>1</sup> Adolescent girls are also vulnerable to other sexually transmitted infections (STIs) and unintended pregnancies.<sup>2</sup> Adolescents are predisposed to minimal family support, age-disparate sexual relationships and financial dependency on sexual partners, and unable to negotiate condom use.<sup>2</sup> As of 2019, adolescents in low/middle-income countries (LMICs) had 21 million pregnancies each year.<sup>1</sup> In South Africa, between 2017 and 2021, the birth rate increased from 49.6 to 55.6 per 1000 girls.<sup>3</sup> There is also a growing concern over the high prevalence of curable STIs among adolescent girls and young women (15–24 years) in South Africa.<sup>4</sup> Adolescent pregnancies are considered at high

risk of adverse pregnancy outcomes and neonatal morbidity, and STIs have been associated with preterm births, low birth weight, and neonatal morbidity and mortality.<sup>5–12</sup> While a high prevalence of asymptomatic STIs and bacterial vaginosis (BV) in adult pregnancies (>19 years of age) is well documented,<sup>13–15</sup> the prevalence and clinical presentation of STIs in adolescent pregnancies are understudied.<sup>16–18</sup>

Frequent condomless sex during pregnancy has been reported since 2013 in several studies in South Africa and other sub-Saharan countries<sup>19–21</sup> and reasons for limited condom use during pregnancy include low perception of risk, cultural myths and gender–power imbalance in relationships.<sup>22</sup> Given the above evidence of continued risk during pregnancy, studies reporting HIV incidence in pregnancy have provided the basis for the need for repeat testing in pregnancy with an intention to initiate antiretroviral treatment and prevent mother-to-child transmission and adverse pregnancy outcomes.<sup>23–24</sup> Similarly, repeat testing for syphilis and prompt treatment are widely adopted in antenatal care guidelines to prevent congenital syphilis and adverse pregnancy outcomes.<sup>25–26</sup> There is a paucity of incidence data for other STIs in pregnant women in general and adolescents in particular.

In this secondary retrospective data analysis of the CAP 088 HIV Incidence Cohort Study that enrolled pregnant women without HIV, we report the prevalence of asymptomatic aetiologically confirmed STIs and BV among pregnant adolescents, and pregnant women 20–24 years and >25 years of age. We further report on incident and persistent/recurrent STIs in all age groups following repeat aetiological testing of vaginal swabs collected in the third trimester and finally evaluated the test performance of syndromic management for all pregnant women.

## METHODS

The CAP 088 cohort study was conducted at three primary healthcare (PHC) clinics in Umlazi, a periurban township in Durban, KwaZulu-Natal. The population of Umlazi is estimated to be between 500 000 and 800 000, residing in formal and informal housing, and whose socioeconomic status is largely low income. A prestudy facility assessment conducted in July–September 2016 revealed an average antenatal HIV prevalence of 36% (297 of 826) at the three PHC clinics in Umlazi. The STI prevalence among pregnant women with HIV in the Umlazi subdistrict was approximately 32%.<sup>27</sup> At the first antenatal visit, women received standard HIV counselling and testing by Department of Health staff and screened by research nurses for participation in an HIV incidence cohort study between February 2017 and March 2018. Pregnant women who tested positive for HIV, were >28 weeks of gestation, in labour or with severe obstetric complications were excluded. In addition, women who did not intend to continue antenatal care at any of study facilities or did not intend to reside in Umlazi for the study period were excluded.

At baseline (first antenatal visit), the research nurse administered a demographic and sexual behaviour questionnaire, examined the participant for symptoms of genital tract infections (GTIs) (abnormal vaginal discharge and genital blisters or sores), collected three vaginal swabs for BV and STI testing and drew 4 mL of blood (EDTA tube-plasma) for HIV testing (ELISA and point-of-care (POC) testing). Pregnant women were routinely tested for syphilis (*Treponema pallidum*) using the Macro-Vue rapid plasma reagin (RPR) qualitative card test. These procedures were repeated at a subsequent antenatal visit after 34 weeks' gestation.

HIV-1 testing with POC tests: the Rapid Anti-HIV (1 and 2) Test Card (Advanced Quality, InTec PRODUCTS, USA) was the HIV screening test at each study visit. Women who tested positive had a second POC test (TRILINE HIV-1/2 Rapid Test, ABON Biopharm, China) to confirm infection. Blood samples sent to the laboratory for storage were used to confirm HIV infection by RNA PCR (ROCHE Ampliprep-TaqMan V.2.0) and a western blot assay (Food and Drug Administration-approved BIORAD Genetics western blot kit) if POC test results were positive.

Vaginal swabs were collected at baseline (first and second trimesters) and repeat study visit (third trimester) and transported to the central laboratory for Gram staining to diagnose BV with Nugent's criteria (a score of 0–3 was considered BV negative, 4–6 intermediate BV and 7–10 BV positive), and the remaining swabs were stored at –70°C until the end of the cohort study. A qualified laboratory technologist read the slides to determine Nugent score. A stored vaginal swab was tested for *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Mycoplasma genitalium* and *Trichomonas vaginalis* using the Roche Light Cycler 480 and Roche STI kits (Roche Diagnostics, USA).

Pregnant women symptomatic for STIs were treated empirically with single doses of azithromycin (1 g oral dose), ceftriaxone (250 mg intramuscular injection) and metronidazole (2 g oral dose) as per the National Department of Health Guidelines for STI management.<sup>25</sup> Women who tested positive for BV were contacted telephonically to return to the clinic for treatment (400 mg metronidazole two times per day for 7 days).


## Statistical analyses

Demographic characteristics (age and occupation) and relationship/behavioural characteristics (partner's age, living together, partner's HIV status, coital frequency, concurrent sexual partners, forced to have condomless sex) were compared between pregnant adolescents (15–19 years), young women (20–24 years) and older pregnant women (>24 years) using  $\chi^2$  tests for categorical data and t-tests or Mann-Whitney for numerical data. Prevalence (95% CIs) of STIs and BV was calculated at baseline as the proportion (%) of all pregnant women who tested positive for each of the STIs and BV separately and as a composite number of pregnant women with a positive test for any STI. To estimate incidence during pregnancy, each STI and BV were examined separately with follow-up time for pregnant women who first tested negative at baseline and positive at the repeat visit calculated from date of baseline visit to the repeat visit. Incidence rates in person years (py) were calculated for each STI and BV and for any STI (composite). We also present the proportion of women who tested positive for STIs at baseline and again at a subsequent visit. Using binary logistic regression to estimate OR and 95% CI, we compared the prevalence and incidence of STIs between adolescents (15–19 years) and 20–24 years and between adolescents and >24 years age group.

Women who returned for a repeat visit were compared with women who did not return (lost to follow-up) for factors that may have increased their risk of incident STIs and BV. The performance characteristics of syndromic diagnosis (sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) were evaluated against laboratory diagnosis of stored specimens at end of study.

## RESULTS

A total of 752 pregnant women who tested negative for HIV-1 at their first antenatal visit were enrolled at a median gestational age of 17 (IQR 12–21) weeks, among whom 180 (23.9%), 291



**Figure 1** Cohort diagram of participant testing for GTI's.

(38.7%) and 281 (37.4%) were in the 15–19, 20–24 and >25 years age groups, respectively (figure 1).

Characteristics of pregnant women are reported in table 1. Overall, 650 (86.4%) were unmarried and not cohabiting with their sexual partner. Pregnant women reported an average of 10 unprotected sex acts in the last 3 months and 18 (2.4%) reported concurrent sexual partners. Nineteen women (2.5%) reported they were aware of their sexual partner's positive HIV status. Adolescents did not differ from their older counterparts in behavioural characteristics, except for a sexual partner who was 5 or more years older. The majority of adolescents (72.6%)

and more than half of women 20–24 years old reported that their sexual partners were 5 years or older when compared with the >25 years (18.6%) age group ( $p < 0.0001$ ; table 1).

At baseline (14–28 weeks' gestation), 244 (32.5%) tested positive for at least one STI (95% CI 29.2 to 35.9) and 280 (37.5%) tested positive for BV (95% CI 34.1 to 41.1). Thirty-two women (4.3%) tested positive for two or more STIs. The women aged 20–24 and >25 years old had a higher but comparable prevalence of STIs than adolescents (15–19 years) (26.7% vs 34.7%: OR 1.4; 95% CI 1.0 to 2.1,  $p = 0.09$  and 26.7% vs 33.8%: OR 1.4; 95% CI 0.9 to 2.1,  $p = 0.12$ , respectively) (table 2). The most prevalent STIs were *T. vaginalis* (15.1%), *C. trachomatis* (9.8%) and *N. gonorrhoeae* (5.7%). In adolescents, prevalence of *T. vaginalis*, *C. trachomatis* and *N. gonorrhoeae* was 11.1%, 7.8% and 4.4%, respectively. The overall prevalence of BV was 37.5% (table 2).

At baseline, 106 (43.4%) women with an STI were symptomatic (predominantly abnormal vaginal discharge) and received empirical treatment (ceftriaxone, azithromycin and metronidazole). The sensitivity, specificity, NPV and PPV of syndromic management in this cohort in the second trimester were 43.4%, 59.4%, 68.6% and 34%, respectively (table 3).

Of 752 pregnant women enrolled in the second trimester, 462 (61.4%) women returned for their follow-up visit in the third trimester (figure 1), comprising 106 (58.9%), 173 (59.1%) and 183 (65.1%) women in the 15–19, 20–24 and >25 years age groups, respectively. Women who returned for a follow-up visit were comparable with women who did not return except for women who returned for a follow-up study visit had a significantly higher prevalence of *T. vaginalis* (18.8%) at baseline than women who did not return (9.7%) (online supplemental table).

**Table 1** Demographic and behavioural characteristics of pregnant adolescents in comparison with other age categories

| Variable   | All women  | 15–19 years    | 20–24 years | >25 years   | P value |
|--|------------|----------------|-------------|-------------|---------|
|  | N=752      | N=180          | N=291       | N=281       |         |
| Age, median (IQR)                                    | 23 (20–27) | 18 (17–19)     | 22 (21–23)  | 28 (26–32)  | —       |
| Gestational age (weeks) at 1st booking, median (IQR) | 17 (13–22) | 17 (12.5–22.5) | 17 (13–22)  | 17 (12–21)  | 0.532   |
| Gravidity, mean (SD)                                 | 1.7 (0.9)  | 1.7 (0.8)      | 1.7 (0.9)   | 1.7 (0.9)   | 0.496   |
| Occupation, n (%)                                    |            |                |             |             |         |
| Employed   | 191 (25.4) | 49 (27.2)      | 73 (25.1)   | 69 (24.6)   | 0.919   |
| Student  | 255 (33.9) | 62 (34.4)      | 91 (31.3)   | 102 (36.3)  |         |
| Unemployed/at home                                   | 306 (40.7) | 69 (38.3)      | 127 (43.6)  | 110 (39.1)  |         |
| Partner's age (years), median (IQR)                  | 27 (23–31) | 26 (23–30)     | 27 (24–31)  | 27 (23–32)  | 0.393   |
| Partner >5 years older, n (%)                        | 331 (44.0) | 130 (72.6)     | 149 (51.4)  | 52 (18.6)   | <0.0001 |
| Relationship status, n (%)                           |            |                |             |             |         |
| Living together                                      | 98 (13.0)  | 25 (13.9)      | 37 (12.7)   | 36 (12.8)   | 0.354   |
| Not living together                                  | 650 (86.4) | 155 (86.1)     | 251 (86.3)  | 244 (86.8)  |         |
| Missing data (n)                                     | 4          | 0              | 3           | 1           |         |
| Coital frequency in the last 3 months, mean (SD)     |            | 9.6 (10.9)     | 9.9 (10.2)  | 10.4 (11.4) | 0.78    |
| Concurrent sexual partners, n (%)                    | 10 (10.8)  | 3 (2.9)        | 9 (5.2)     | 6 (4.1)     | 0.283   |
| Forced to have unprotected sex, n (%)                | 18 (2.4)   | 6 (3.4)        | 8 (2.8)     | 11 (3.9)    | 0.738   |
| Partner's HIV status, n (%)                          |            |                |             |             |         |
| Negative   | 441 (58.6) | 100 (55.6)     | 185 (63.6)  | 156 (55.5)  | 0.084   |
| Positive   | 19 (2.5)   | 2 (1.1)        | 6 (2.1)     | 11 (3.9)    |         |
| Unknown  | 291 (38.7) | 77 (42.8)      | 100 (34.4)  | 114 (40.6)  |         |
| Missing data   | 1          | 1              | 0           | 0           |         |
| Symptomatic for GTI at baseline, n                   | 312        | 82             | 111         | 119         | 0.48    |
| Abnormal vaginal discharge, n (%)                    | 303 (97.1) | 80 (97.6)      | 107 (96.4)  | 116 (97.5)  |         |
| Genital sores/blisters, n (%)                        | 9 (2.9)    | 2 (2.4)        | 4 (3.6)     | 3 (2.5)     |         |

GTI, genital tract infection.

**Table 2** Prevalence of genital tract infections at baseline in adolescents in comparison with other age categories

|  | All women<br>(n=752)         | 15–19 years<br>(n=180)      | 20–24 years<br>(n=291)       | ≥25 years<br>(n=281)         | 20–24 vs 15–19 years (ref) | ≥25 vs 15–19 years (ref) |
|--|------------------------------|-----------------------------|------------------------------|------------------------------|----------------------------|--------------------------|
|  |                              |                             |                              |                              | OR (95% CI)<br>P value     | OR (95% CI)<br>P value   |
| <i>Trichomonas vaginalis</i> , n (%)<br>(95% CI) | 115 (15.1)<br>(13.0 to 18.2) | 20 (11.1)<br>(7.0 to 16.9)  | 50 (17.2)<br>(13.0 to 22.0)  | 45 (16.0)<br>(12.1 to 21.1)  | 1.6 (0.9 to 2.8)<br>0.09   | 1.5 (0.9 to 2.7)<br>0.17 |
| <i>Neisseria gonorrhoeae</i> , n (%)<br>(95% CI) | 43 (5.7)<br>(4.3 to 7.7)     | 8 (4.4)<br>(2.0 to 8.7)     | 17 (5.8)<br>(3.4 to 9.2)     | 18 (6.4)<br>(3.9 to 10.0)    | 1.3 (0.6 to 3.1)<br>0.57   | 1.5 (0.6 to 3.4)<br>0.42 |
| <i>Chlamydia trachomatis</i> , n (%)<br>(95% CI) | 73 (9.8)<br>(7.9 to 12.1)    | 14 (7.8)<br>(4.4 to 12.9)   | 33 (11.3)<br>(7.9 to 15.6)   | 26 (9.3)<br>(6.2 to 13.4)    | 1.5 (0.8 to 2.9)<br>0.27   | 1.2 (0.6 to 2.4)<br>0.62 |
| <i>Mycoplasma genitalium</i> , n (%)<br>(95% CI) | 26 (3.5)<br>(2.4 to 5.1)     | 9 (5.0)<br>(2.4 to 9.4)     | 7 (2.4)<br>(1.0 to 4.9)      | 10 (3.6)<br>(1.8 to 6.5)     | 0.5 (0.2 to 1.3)<br>0.19   | 0.7 (0.3 to 1.8)<br>0.48 |
| <i>Treponema pallidum</i> , n (%)<br>(95% CI)    | 4 (0.5)<br>(0.2 to 1.4)      | 0 (0.0)                     | 1 (0.3)<br>(0.01 to 1.9)     | 3 (1.1)<br>(0.2 to 3.1)      | N                          | N/A                      |
| Any STI, n (%)<br>(95% CI)                       | 244 (32.5)<br>(29.2 to 35.9) | 48 (26.7)<br>(20.4 to 33.8) | 101 (34.7)<br>(29.3 to 40.5) | 95 (33.8)<br>(28.3 to 39.7)  | 1.4 (1.0 to 2.1)<br>0.09   | 1.4 (0.9 to 2.1)<br>0.12 |
| Bacterial vaginosis, n (%)<br>(95% CI)           | 280 (37.5)<br>(34.1 to 41.1) | 63 (35.0)<br>(28.4 to 42.9) | 107 (36.8)<br>(31.4 to 42.9) | 110 (39.2)<br>(33.7 to 45.4) | 1.1 (0.7 to 1.6)<br>0.77   | 1.2 (0.8 to 1.8)<br>0.37 |

STI, sexually transmitted infection.

At the repeat visit, 66 of 170 (38.8%) pregnant women who tested positive for at least one STI at baseline subsequently tested positive, comprising 11 (37.9%), 27 (40.9%) and 28 (37.3%) women in the 15–19, 20–24 and >25 years age categories, respectively (table 4). The most recurrent or persistent infections were *T. vaginalis* (11.5%), *C. trachomatis* (12.0%) and *N. gonorrhoeae* (9.4%). Overall, 38.8% tested positive again at the repeat visit. Thirty-eight (57.6%) women with persistent infections at the repeat visit were asymptomatic at baseline and did not receive empirical treatment.

Overall, 40.7% (118 of 290) who tested negative for any STI at baseline tested positive for an STI at the repeat visit in late pregnancy over a cumulative period of 605 months, with an incidence rate of 19.5 per 100 py. Incidence rates of any STI during pregnancy were 23.9/100 py, 20.5/100 py and 16.2/100 py in the 15–19 years, 20–24 years and >25 years age categories, respectively (table 4). When compared with the adolescents (15–19 years), the odds of incident STIs in the 20–24 (OR 1.1; 95% CI 0.6 to 1.9,  $p=0.88$ ) and >25 years (OR 0.8; 95% CI 0.5 to 1.5,  $p=0.54$ ) age categories were not significant.

The most common new infections were *T. vaginalis* (9.6/100 py), *N. gonorrhoeae* (9.3/100 py) and *C. trachomatis* (11.6/100 py). The 15–19 years age group had a higher incidence of *T. vaginalis* (14.2/100 py) than the other age groups. At the repeat visit, 19.0% (35 of 184) with any STI were symptomatic and received empirical treatment. The specificity, NPV and PPV of syndromic management in the third trimester were 75.7%, 58.4% and 34.3%, respectively (table 3).

There were seven (1.5%) HIV seroconversions in late pregnancy: one (0.9%) adolescent, five (2.9%) in the 20–24 years age group and one (0.5%) in the >25 years age group. The overall HIV incidence rate during pregnancy was 1.2/100 py. The highest HIV incidence rate was reported among the 20–24 years age group (2.2/100 py) (table 3). Of the seven pregnant

women who seroconverted, two (28.6%) tested positive for *N. gonorrhoeae*, two (28.6%) for *T. vaginalis*, one (14.3%) for *C. trachomatis* and four (57.1%) for BV. All infections were detected at baseline. None of the seroconvertors tested positive for an STI at the repeat visit.

## DISCUSSION

Our retrospective cohort data analysis confirms high prevalence of asymptomatic STIs and BV in pregnant women not living with HIV. Overall, one-third of the pregnant women tested positive for at least one STI at their first antenatal visit in the first or second trimester, the common STIs being *T. vaginalis* (15.1%), *C. trachomatis* (9.8%) and *N. gonorrhoeae* (5.7%). One in four (26.7%) adolescents (15–19 years) tested positive for an STI at their first antenatal visit, not significantly lower than older counterparts 20–24 years (34.7%) and >25 years (33.8%). Consistent with other studies, 56.6% of women with a GTI were asymptomatic and not treated, while 40.6% of pregnant women received syndromic treatment unnecessarily. Our cohort study is one among a handful of studies that reports a high incidence of asymptomatic STIs in pregnant women who returned for their third trimester visit.<sup>14 18 28</sup> Overall, 40.7% of pregnant women tested positive for an STI for the first time at repeat testing. Pregnant adolescents (15–19 years) had a high incidence of STIs in the third trimester (23.9/100 py) but not significantly higher than the women 20–24 years old (20.5/100 py) and women >25 years (16.2/100 py). When compared with baseline, a much higher proportion (>70%) of all pregnant women with a positive STI result at repeat testing were asymptomatic and not treated. Our study further reports a lower HIV incidence rate (1.2/100 py) in pregnancy when compared with a meta-analysis of earlier studies (7.4/100 py). Adolescent girls had a lower HIV incidence than the pregnant women 20–24 years old (0.7/100 py vs 2.2/100 py).

**Table 3** Sensitivity, specificity, NPV and PPV of syndromic management of genital tract infections at baseline and third trimester of pregnancy

|                          | Sensitivity (%) | Specificity (%) | NPV            | PPV            |
|--------------------------|-----------------|-----------------|----------------|----------------|
| Baseline (12–28 weeks)   | 106/244 (43.4)  | 302/508 (59.5)  | 302/440 (68.6) | 106/312 (34.0) |
| Repeat visit (>28 weeks) | 35/184 (19.0)   | 209/276 (75.7)  | 209/358 (58.4) | 35/102 (34.3)  |

NPV, negative predictive value; PPV, positive predictive value.

**Table 4** Repeat and incident genital tract infections at follow-up visit (third trimester of pregnancy) by age category

| N/A   | All women<br>(n=462)<br>Pos/tested (%) | 15–19 years<br>(n=106)<br>Pos/tested (%) | 20–24 years<br>(n=173)<br>Pos/tested (%) | >25 years<br>(n=183)<br>Pos/tested (%) | 20–24 vs 15–19<br>years<br>OR (95% CI)<br>P value | >25 vs 15–19<br>years<br>OR (95% CI)<br>P value |
|---|--|--|--|--|---|---|
| <i>Trichomonas vaginalis</i>  |  |  |  |  |   |   |
| Repeat infection  | 10/87 (11.5)                           | 1/10 (10.0)                              | 3/38 (7.9)                               | 6/39 (15.4)                            | 0.8 (0.1 to 8.3)<br>1.00                          | 1.6 (0.2 to 15.4)<br>1.00                       |
| New infection   | 58/375 (15.5)                          | 19/96 (19.8)                             | 25/135 (18.5)                            | 14/144 (9.7)                           | 0.9 (0.5 to 1.8)<br>0.87                          | 0.4 (0.2 to 0.9)<br>0.03*                       |
| Incidence rate  | 9.6/100 py                             | 14.2/100 py                              | 11.1/100 py                              | 5.7/100 py                             |   |   |
| <i>Neisseria gonorrhoeae</i>  |  |  |  |  |   |   |
| Repeat infection  | 3/32 (9.4)                             | 0/5 (0)                                  | 2/12 (16.7)                              |  |   | N/A   |
| New infection   | 56/430 (13.0)                          | 14/101 (13.9)                            | 22/161 (13.7)                            | 20/168 (11.9)                          | 0.9 (0.5 to 2.0)<br>1.0                           | 0.8 (0.4 to 1.7)<br>0.71                        |
| Incidence rate  | 9.3/100 py                             | 10.5/100 py                              | 9.8/100 py                               | 8.1/100 py                             |   |   |
| <i>Chlamydia trachomatis</i>  |  |  |  |  |   |   |
| Repeat infection  | 6/50 (12.0)                            | 1/10 (10.0)                              | 2/23 (8.7)                               | 3/17 (17.7)                            | 0.9 (0.1 to 10.7)<br>1.00                         | 1.9 (0.2 to 21.5)<br>1.00                       |
| New infection   | 70/412 (17.0)                          | 12/96 (12.5)                             | 27/150 (18.0)                            | 31/166 (18.7)                          | 1.5 (0.7 to 3.2)<br>0.29                          | 1.6 (0.8 to 3.3)<br>0.23                        |
| Incidence rate  | 11.6/100 py                            | 9.0/100 py                               | 12.0/100 py                              | 12.6/100 py                            |   |   |
| <i>Mycoplasma genitalium</i>  |  |  |  |  |   |   |
| Repeat infection  | 0/19                                   | 0/6                                      | 0/6                                      | 0/7                                    | N/A   | N/A   |
| New infection   | 21/443 (4.7)                           | 2/100 (2.0)                              | 8/167 (4.8)                              | 5/176 (2.8)                            | 2.5 (0.5 to 11.8)<br>0.33                         | 1.4 (0.3 to 7.5)<br>1.00                        |
| Incidence rate  | 3.5/100 py                             | 1.5/100 py                               | 3.6/100 py                               | 2.0/100 py                             |   |   |
| <i>Treponema pallidum</i> *   |  |  |  |  |   |   |
| Missing results   | 157                                    | 32                                       | 65                                       | 60                                     | N/A   | N/A   |
| Repeat infection  | 0/1                                    | 0  | 0  | 0/1                                    |   |   |
| New infection   | 1/304 (0.3)                            | 0/74 (0.0)                               | 0/108 (0.0)                              | 1/122 (0.8)                            | N/A   | N/A   |
| Incidence rate  | 0.2/100 py                             | 0  | 0  | 0.4/100 py                             |   |   |
| Women positive for any STI at baseline and at repeat visit          | 66/170 (38.8)                          | 11/29 (37.9)                             | 27/66 (40.9)                             | 28/75 (37.3)                           | 1.1 (0.5 to 2.8)<br>0.82                          | 0.9 (0.4 to 2.4)<br>1.00                        |
| Women negative for any STI at baseline and positive at repeat visit | 118/292 (40.4)                         | 32/77 (41.6)                             | 46/107 (43.0)                            | 40/108 (37.0)                          | 1.1 (0.6 to 1.9)<br>0.88                          | 0.8 (0.5 to 1.5)<br>0.54                        |
| Incidence rate  | 19.5/100 py                            | 23.9/100 py                              | 20.5/100 py                              | 16.2/100 py                            |   |   |
| HIV-1   |  |  |  |  |   |   |
| New infection   | 7/462 (1.5)                            | 1/106 (0.9)                              | 5/173 (2.9)                              | 1/183 (0.5)                            | 3.1 (0.4 to 21.1)<br>0.41                         | 0.6 (0.04 to 9.3)<br>1.00                       |
| Incidence rate  | 1.2/100 py                             | 0.7/100 py                               | 2.2/100 py                               | 0.4/100 py                             |   |   |

\*Missing results for repeat visits; depended on facility-based routine testing.  
py, person years; STI, sexually transmitted infection.

High prevalence of asymptomatic STIs in pregnancy has been commonly reported in LMICs and higher prevalence of *T. vaginalis*, *N. gonorrhoeae* and *C. trachomatis* reported in Southern Africa.<sup>13</sup> In our study, 27% of adolescents tested positive for any STI at antenatal registration and although the prevalence was lower than their older counterparts, we report a notably higher prevalence than other studies of adolescent pregnancies (11%–19%).<sup>9 16 29</sup> While adolescents had a lower prevalence of *T. vaginalis* (11.1%), *N. gonorrhoeae* (4.4%) and *C. trachomatis* (7.8%) in comparison with their older counterparts, *M. genitalium* was more prevalent in pregnant adolescents (5.0%; 95% CI 2.4% to 9.4%) than in other age categories (2.4% and 3.6%).

Consistent with several studies conducted in sub-Saharan Africa, the prevalence estimates of predominantly asymptomatic STIs in our study further support the need for POC testing and targeted treatment during pregnancy.<sup>10 15 30</sup> The WHO, while

acknowledging that syndromic management is simple and assures rapid, same-day treatment, is also cognisant of disadvantages of syndromic management in the overtreatment and missed treatment as the majority of STIs are asymptomatic.<sup>31</sup> We report suboptimal sensitivity (43%) and PPV (34%) of syndromic diagnosis in the first or second trimester. Moreover, we report 30% of pregnant women without any STI or BV received antibiotic treatment unnecessarily in the second trimester. Syndromic diagnosis in the third trimester had a much lower sensitivity (19%), although a lower proportion (24%) of pregnant women without an STI received antibiotic treatment unnecessarily. Our findings further support the need for aetiological rescreening for STIs prior to delivery.

Repeat testing for STIs revealed a high incidence of predominantly asymptomatic STIs (19.5/100 py) with a comparably high incidence rate among pregnant adolescents (23.9/100

py) versus women 20–24 years (20.5/100 py) and >25 years (16.2/100 py). Adolescents had a higher incidence of *T. vaginalis* (14.2/100 py) than women 20–24 years (11.1/100 py) and >25 years (5.7/100 py). In an urban adolescent pregnant cohort in the USA, rescreening in the third trimester yielded 9% (9 of 95) and 3% (3 of 95) recurrent *C. trachomatis* and *N. gonorrhoeae* infections, respectively, while 4% (4 of 95) had new *C. trachomatis* and *N. gonorrhoeae* infections.<sup>18</sup> At repeat testing, we detected new *T. vaginalis*, *N. gonorrhoeae* and *C. trachomatis* infections in 19.8%, 13.9% and 12.5% of adolescents, respectively. Our findings further support the conclusion of others that adolescents continue to have unprotected sex during pregnancy and therefore at continued risk of acquiring STIs and HIV-1.<sup>22 23</sup> In a secondary data analysis from the MIRA Study conducted between 2003 and 2006 in South Africa and Zimbabwe, the study reported an incidence rate of 9.2/100 py for *T. vaginalis* in pregnant women not living with HIV, similar to our study finding (9.6/100 py).<sup>28</sup> However, our study reports a higher incidence of *C. trachomatis* (11.6/100 py) and *N. gonorrhoeae* (9.3/100 py) than the MIRA Study (9.9/100 py and 4.9/100 py, respectively), therefore emphasising the need for rescreening and targeted treatment later in pregnancy. Current Centers for Disease Control and Prevention recommendations include rescreening for STIs in the third trimester, a strategy absent in the WHO and South African Guidelines.<sup>26 31 32</sup>

Repeat POC testing for HIV-1 in the third trimester in our study cohort as per national guidelines revealed seven HIV seroconversions (1.5%), including one adolescent (0.9%) and the majority in the 20–24 years age group (2.9%). Incidence of syphilis in our study was unexpectedly low with only one new syphilis case (0.9%) in older women in the third trimester. The HIV seroconversion rate in our pregnant cohort like that of recent cohort studies in Uganda and Kenya is relatively low, hence limiting the power to ascertain an association between STIs and HIV acquisition.<sup>24 33</sup>

While our study provides some novel evidence that could change public health practice, it is not without limitations. First, we depended on routine testing for syphilis. At the PHCs, an RPR test was conducted by PHC staff and we did not confirm with laboratory-based TPFA testing. Second, only 60% of pregnant women returned for their subsequent study visit, hence limiting generalisability of findings. Lastly, we were unable to differentiate recurrent from persistent infections at repeat testing. Furthermore, we did not collect partner STI data to confirm recurrent infections in pregnant women at the repeat visit.

## CONCLUSIONS

Prevalence of largely asymptomatic GTIs in adolescents at first antenatal registration is high but comparable with older women, thus necessitating aetiological screening tests for all antenatal attendees. Adolescents and young women are at risk of asymptomatic incident STIs in the third trimester. We provide novel evidence supporting repeat testing for STIs in pregnancy.

**Handling editor** Jo Gibbs

**Twitter** Vani Govender @VaniChetty4

**Acknowledgements** Data Management Team, research nurses and laboratory technicians.

**Contributors** VG and DM conceptualised this study and drafted the manuscript. DM is responsible for the overall study content. CC provided statistical support and reviewed the manuscript. MN, QAK and SN provided feedback on the draft and subsequent revisions. MN was the clinician on the study and guided the syndromic

management of BV and STIs in this study. QAK helped conceptualise and secured funding for the parent study. SN performed the STI screening.

**Funding** The study was conducted under a grant funded by Family Health International 360 under Cooperative Agreement/Grant No. AID-674-A-14-00009 funded by USAID Southern Africa. Additional funding for STI testing was received from University of KwaZulu-Natal.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** This study involves human participants and institutional regulatory oversight was provided by the University of KwaZulu-Natal Biomedical Research Ethics Committee (BE 194/18). Women were asked to provide written informed consent for participation in the study and for storage of biological specimens for future research.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. Data available on reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iD

Vani Govender <http://orcid.org/0000-0003-1577-6381>

## REFERENCES

- 1 WHO fact sheet, 15 September 2022. Adolescent pregnancy. 2022. Available: <https://www.who.int/news-room/fact-sheets/detail/adolescent-pregnancy> [Accessed 27 Dec 2022].
- 2 Hlongwa M, Mashamba-Thompson T, Makhunga S, *et al*. Evidence on factors influencing contraceptive use and sexual behavior among women in South Africa: a scoping review. *Medicine (Baltimore)* 2020;99:e19490.
- 3 Barron P, Subedar H, Letsoko M, *et al*. Teenage births and pregnancies in South Africa, 2017–2021—a reflection of a troubled country: analysis of public sector data. *S Afr Med J* 2022;112:252–8.
- 4 Francis SC, Mthiyane TN, Baisley K, *et al*. Prevalence of sexually transmitted infections among young people in South Africa: a nested survey in a health and demographic surveillance site. *PLoS Med* 2018;15:e1002512.
- 5 Grant JS, Chico RM, Lee AC, *et al*. Sexually transmitted infections in pregnancy: a narrative review of the global research gaps, challenges, and opportunities. *Sex Transm Dis* 2020;47:779–89.
- 6 Mombo-Ngoma G, Mackanga JR, González R, *et al*. Young adolescent girls are at high risk for adverse pregnancy outcomes in sub-Saharan Africa: an observational multicountry study. *BMJ Open* 2016;6:e011783.
- 7 Ganchimeg T, Ota E, Morisaki N, *et al*. Pregnancy and childbirth outcomes among adolescent mothers: a World Health organization multicountry study. *BJOG* 2014;121 Suppl 1:40–8.
- 8 Althabe F, Moore JL, Gibbons L, *et al*. Adverse maternal and perinatal outcomes in adolescent pregnancies: the global network's maternal newborn health registry study. *Reprod Health* 2015;12:Suppl
- 9 Borges-Costa J, Matos C, Pereira F. Sexually transmitted infections in pregnant adolescents: prevalence and association with maternal and foetal morbidity. *J Eur Acad Dermatol Venereol* 2012;26:972–5.
- 10 Nyemba DC, Peters RPH, Medina-Marino A, *et al*. Impact of aetiological screening of sexually transmitted infections during pregnancy on pregnancy outcomes in South Africa. *BMC Pregnancy Childbirth* 2022;22:194.
- 11 Warr AJ, Pintye J, Kinuthia J, *et al*. Sexually transmitted infections during pregnancy and subsequent risk of stillbirth and infant mortality in Kenya: a prospective study. *Sex Transm Infect* 2019;95:60–6.
- 12 Ravindran J, Richardson BA, Kinuthia J, *et al*. Chlamydia, gonorrhoea, and incident HIV infection during pregnancy predict preterm birth despite treatment. *J Infect Dis* 2021;224:2085–93.

- 13 Joseph Davey DL, Shull HI, Billings JD, *et al.* Prevalence of curable sexually transmitted infections in pregnant women in low- and middle-income countries from 2010 to 2015: a systematic review. *Sex Transm Dis* 2016;43:450–8.
- 14 Nyemba DC, Medina-Marino A, Peters RPH, *et al.* Prevalence, incidence and associated risk factors of stis during pregnancy in South Africa. *Sex Transm Infect* 2021;97:375–81.
- 15 Chaponda EB, Bruce J, Michelo C, *et al.* Assessment of syndromic management of curable sexually transmitted and reproductive tract infections among pregnant women: an observational cross-sectional study. *BMC Pregnancy Childbirth* 2021;21:98.
- 16 Fuchs E, Dwiggins M, Lokken E, *et al.* Influence of sexually transmitted infections in pregnant adolescents on preterm birth and chorioamnionitis. *Infect Dis Obstet Gynecol* 2020;2020:1908392.
- 17 Redelinghuys MJ, Ehlers MM, Dreyer AW, *et al.* A cross-sectional study on the relationship of age, gestational age and HIV infection to bacterial vaginosis and genital Mycoplasma infection. *BMJ Open* 2015;5:e008530.
- 18 Berggren EK, Patchen L. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae and repeat infection among pregnant urban adolescents. *Sex Transm Dis* 2011;38:172–4.
- 19 Theuring S, Rubagumya K, Schumann H, *et al.* Sexual risk behavior in HIV-uninfected pregnant women in Western Uganda. *Arch Sex Behav* 2021;50:3277–86.
- 20 Kinuthia J, Drake AL, Matemo D, *et al.* Hiv acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics. *AIDS* 2015;29:2025–33.
- 21 Peltzer K, Mlambo G. Sexual HIV risk behaviour and associated factors among pregnant women in Mpumalanga, South Africa. *BMC Pregnancy Childbirth* 2013;13:57.
- 22 Joseph Davey D, Farley E, Gomba Y, *et al.* Sexual risk during pregnancy and postpartum periods among HIV-infected and -uninfected South African women: implications for primary and secondary HIV prevention interventions. *PLoS ONE* 2018;13:e0192982.
- 23 Drake AL, Wagner A, Richardson B, *et al.* Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. *PLoS Med* 2014;11:e1001608.
- 24 Mushamiri I, Adukans M, Apat D, *et al.* Optimizing PMTCT efforts by repeat HIV testing during antenatal and perinatal care in resource-limited settings: a longitudinal assessment of HIV seroconversion. *PLoS One* 2020;15:e0233396.
- 25 Hersh AR, Megli CJ, Caughey AB. Repeat screening for syphilis in the third trimester of pregnancy: a cost-effectiveness analysis. *Obstet Gynecol* 2018;132:699–707.
- 26 Department of Health, South Africa. Sexually transmitted infections management guidelines 2018 adapted from: standard treatment guidelines and essential medicine list PHC. Available: <https://www.health.gov.za/wp-content/uploads/2020/11/sti-guidelines-27-08-19.pdf> [Accessed 28 Sep 2022].
- 27 Moodley D, Moodley P, Sebitloane M, *et al.* High prevalence and incidence of asymptomatic sexually transmitted infections during pregnancy and postdelivery in Kwazulu Natal, South Africa. *Sex Transm Dis* 2015;42:43–7.
- 28 Teasdale CA, Abrams EJ, Chiasson MA, *et al.* Incidence of sexually transmitted infections during pregnancy. *PLoS One* 2018;13:e0197696.
- 29 Niccolai LM, Ethier KA, Kershaw TS, *et al.* Pregnant adolescents at risk: sexual behaviors and sexually transmitted disease prevalence. *Am J Obstet Gynecol* 2003;188:63–70.
- 30 Peters R, Klausner JD, de Vos L, *et al.* Aetiological testing compared with syndromic management for sexually transmitted infections in HIV-infected pregnant women in South Africa: a non-randomised prospective cohort study. *BJOG* 2021;128:1335–42.
- 31 World Health Organisation. Guidelines for the management of symptomatic sexually transmitted infections. 2021. Available: <https://www.who.int/publications/i/item/9789240024168> [Accessed 28 Sep 2022].
- 32 Workowski KA, Bachmann LH, Chan PA, *et al.* Sexually transmitted infections treatment guidelines, 2021. *MMWR Recomm Rep* 2021;70:1–187.
- 33 Schumann H, Rubagumya K, Rubaihayo J, *et al.* The incidence of HIV and associated risk factors among pregnant women in Kabarole district, Uganda. *PLoS One* 2020;15:e0234174.

**Supplementary Table: Characteristics of Women who did not return for followup in comparison with women who returned for 3<sup>rd</sup> trimester study visit**

| Variable                                  | Participants Returned | Participants Lost to Followup | P Value |
|---|-----------------------|-------------------------------|---------|
|   | N=462                 | N=290                         |         |
| <b>Age, mean (SD)</b>                     | 23.8 (5.1)            | 23.4 (5.3)                    | 0.244   |
| <20 years n (%)                           | 106 (22.9)            | 74 (25.5)                     |         |
| >20 years n (%)                           | 356 (77.1)            | 216 (74.5)                    | 0.483   |
| <b>Relationship n (%)</b>                 |                       |                               |         |
| Living with Partner                       | 60 (13.0)             | 38 (13.1)                     | 1.00    |
| Not Living with Partner                   | 402 (87.0)            | 252 (86.9)                    |         |
| <b>Partner &gt;5 years older n (%)</b>    |                       |                               |         |
| Yes                                       | 194 (42.0)            | 137 (47.2)                    | 0.258   |
| No  | 268 (58.0)            | 153 (52.8)                    |         |
| <b>Bacterial Vaginosis n (%)</b>          |                       |                               |         |
| Pos                                       | 158 (34.2)            | 122 (42.1)                    | 0.063   |
| Neg                                       | 304 (65.8)            | 168 (57.9)                    |         |
| <b><i>C. trachomatis</i> n (%)</b>        |                       |                               |         |
| Pos                                       | 50 (10.8)             | 23 (7.9)                      | 0.207   |
| Neg                                       | 412 (89.2)            | 267 (92.1)                    |         |
| <b><i>N. gonorrhoea</i> n (%)</b>         |                       |                               |         |
| Pos                                       | 32 (6.9)              | 11 (3.8)                      | 0.077   |
| Neg                                       | 430 (93.1)            | 279 (96.2)                    |         |
| <b><i>T. vaginalis</i> n (%)</b>          |                       |                               |         |
| Pos                                       | 87 (18.8)             | 28 (9.7)                      | <0.001  |
| Neg                                       | 375 (81.2)            | 262 (90.3)                    |         |
| <b>Symptomatic and Received Treatment</b> |                       |                               |         |
| Yes                                       | 192 (41.6)            | 120 (41.4)                    | 0.820   |
| No  | 270 (58.4)            | 170 (58.6)                    |         |